沃森生物：全资子公司完成工商变更登记

Core Viewpoint - Watson Bio announced a capital increase of 440 million yuan for its wholly-owned subsidiary, Beijing Watson, to support its operational funding needs [1] Group 1 - The capital increase is aimed at ensuring the daily operational funding requirements of Beijing Watson [1] - The company will contribute the capital in installments based on the actual needs of Beijing Watson [1] - After the completion of this capital increase, the company will still hold 100% equity in Beijing Watson [1] Group 2 - Beijing Watson has completed the industrial and commercial change registration procedures for this capital increase and has obtained a new business license from the administrative department [1]